In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor

  • Authors:
    • Senna Sakai
    • Hiroto Izumi
    • Yukiko Yoshiura
    • Yoshifumi Nakayama
    • Takahiro Yamaguchi
    • Yoshikazu Harada
    • Chiho Koi
    • Hiroyuki Kurata
    • Yasuo Morimoto
  • View Affiliations

  • Published online on: September 20, 2016     https://doi.org/10.3892/ol.2016.5156
  • Pages: 4263-4269
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aurora kinase B (AURKB) inhibitors are regarded as potential molecular‑targeting drugs for cancer therapy. The present study evaluated the cytotoxic effect of a combination of AZD1152‑hQPA, an AURKB inhibitor, and various anticancer agents on the HeLa human cervical cancer cell line, as well as its cisplatin‑resistant equivalent HCP4 cell line. It was demonstrated that AZD1152‑hQPA had an antagonistic effect on the cytotoxicity of cisplatin, etoposide and doxorubicin, but had a synergistic effect on that of all‑trans‑retinoic acid (ATRA), Am80 and TAC‑101, when tested on HeLa cells. Cisplatin, etoposide and doxorubicin were shown to increase the cellular expression of AURKB, while ATRA, Am80 and TAC‑101 downregulated its expression. These results suggested that AURKB expression is regulated by these anticancer agents at the transcriptional level, and that the level of expression of AURKB may influence the cytotoxic effect of AZD1152‑hQPA. Therefore, when using anticancer agents, decreasing the expression of AURKB using a molecular‑targeting drug may be an optimal therapeutic strategy.
View Figures
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sakai S, Izumi H, Yoshiura Y, Nakayama Y, Yamaguchi T, Harada Y, Koi C, Kurata H and Morimoto Y: In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor. Oncol Lett 12: 4263-4269, 2016.
APA
Sakai, S., Izumi, H., Yoshiura, Y., Nakayama, Y., Yamaguchi, T., Harada, Y. ... Morimoto, Y. (2016). In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor. Oncology Letters, 12, 4263-4269. https://doi.org/10.3892/ol.2016.5156
MLA
Sakai, S., Izumi, H., Yoshiura, Y., Nakayama, Y., Yamaguchi, T., Harada, Y., Koi, C., Kurata, H., Morimoto, Y."In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor". Oncology Letters 12.5 (2016): 4263-4269.
Chicago
Sakai, S., Izumi, H., Yoshiura, Y., Nakayama, Y., Yamaguchi, T., Harada, Y., Koi, C., Kurata, H., Morimoto, Y."In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor". Oncology Letters 12, no. 5 (2016): 4263-4269. https://doi.org/10.3892/ol.2016.5156